(2-fluoro-3-iodo-phenyl)-methanol | 307975-02-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-fluoro-3-iodo-phenyl)-methanol
• 英文别名: 2-Fluoro-3-iodobenzyl alcohol；(2-fluoro-3-iodophenyl)methanol
• CAS: 307975-02-6
• 化学式: C₇H₆FIO
• 分子量: 252.027
• InChiKey: LKTRXJWENDDHQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2-fluoro-3-iodo-phenyl)-methanol 在 四溴化碳 、 sodium hydride 、 三苯基膦 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (3-{4-[1-(2-Fluoro-3-iodo-benzyloxy)-ethyl]-2-methoxy-5-nitro-phenoxy}-propyl)-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Discovery of selective metal-binding peptoids using 19F encoded combinatorial libraries

  摘要：

  A method for encoding solid-phase split/mix combinatorial libraries using the chemical shift of synthetic fluoroarenes ('F-codes') has been developed. They have wide chemical shift dispersion and are detectable at the sub-mu mol level. F-19 NMR is used for decoding. Nine fluoroarenes bearing linkers for attachment to solid-phase synthesis supports through a photocleavable group were prepared. A library of 90 N-alkylglycines bearings substituted succinamides was prepared on solid phase from nine amines, in which the amine is encoded by the fluorinated tag, and 10 anhydrides. Metal binding studies followed by decoding identified unique, specific binders of copper(II) and iron(III) with mu M K(D)s. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00416-9
• 作为产物：
  描述：

  2-氟-3-碘苯甲腈 在 硼酸三甲酯 、 硫酸 、 dimethyl sulfide borane 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 生成 (2-fluoro-3-iodo-phenyl)-methanol
  参考文献：
  名称：

  Indolin-2-one p38α inhibitors III: Bioisosteric amide replacement

  摘要：

  Crystallographic structural information was used in the design and synthesis of a number of bioisosteric derivatives to replace the amide moiety in a lead series of p38 alpha inhibitors which showed general hydrolytic instability in human liver preparations. Triazole derivative 13 was found to have moderate bioavailability in the rat and demonstrated potent in-vivo activity in an acute model of inflammation. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.006

文献信息

• 联苯类化合物及其制备方法和医药用途
  申请人：中国药科大学

  公开号：CN111909108B

  公开（公告）日：2023-05-02

  本发明公开了联苯类化合物及其制备方法和医药用途，该联苯类化合物结构如式(I)或式(II)所示，本发明的联苯类化合物或其药学上可接受的盐、互变异构体、内消旋体、外消旋体、立体异构体、代谢产物、代谢前体、前药或溶剂化物是PD‑L1抑制剂，对PD‑1和PD‑L1蛋白‑蛋白相互作用具有显著的抑制作用，因而可应用于制备PD‑L1抑制剂，并应用于制备预防或治疗肿瘤、自身免疫性疾病、器官移植排斥、感染性疾病和炎症性疾病的免疫调节剂类药物；
• New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
  申请人：Laboratorios Almirall, S.A.

  公开号：EP2113503A1

  公开（公告）日：2009-11-04

  This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

  这项发明涉及具有一般式(I)的新p38丝裂原活化蛋白激酶抑制剂；其制备方法；包含它们的药物组合物；以及它们在治疗中的应用。
• 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20150158855A1

  公开（公告）日：2015-06-11

  The present invention relates to 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives of formula (I) wherein Ar 1 , Q, and R 1 to R 5 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

  本发明涉及公式（I）中的2-(1,2,3-三唑-2-基)苯甲酰胺和3-(1,2,3-三唑-2-基)吡啶甲酰胺衍生物，其中Ar1、Q和R1至R5如描述所述，以及它们的制备方法，其药学上可接受的盐，以及它们作为药物的用途，含有一个或多个公式（I）化合物的药物组合物，特别是它们作为促进睡眠激素受体拮抗剂的用途。
• SUBSTITUTED INDOLIN-2-ONE DERIVATIVES AND THEIR USE AS P38 MITOGEN-ACTIVATED KINASE INHIBITORS
  申请人：Eastwood Paul Robert

  公开号：US20110046097A1

  公开（公告）日：2011-02-24

  The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

  本公开涉及具有一般式（I）的p38有丝分裂原活化蛋白激酶的新抑制剂，其制备过程，其制药组合物以及其使用方法。
• Substituted indolin-2-one derivatives and their use as P38 mitogen-activated kinase inhibitors
  申请人：Eastwood Paul Robert

  公开号：US08450341B2

  公开（公告）日：2013-05-28

  The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

  本公开涉及具有一般式（I）的p38丝裂原活化蛋白激酶的新抑制剂，其制备方法，药物组合物以及使用方法。